Vineeth Sukrithan - Concepedia

Author

Vineeth Sukrithan

Albert Einstein College of Medicine ORCID

Also Known As

Vineeth K. Sukrithan, Vineeth Sukrithan

137

Publications

655

Citations

H-Index

Concepts

All Affiliations

Albert Einstein College of Medicine The Ohio State University The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

About

Vineeth Sukrithan is an author at Albert Einstein College of Medicine specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	105
2	Cell Biology	2	2	60
3	Immunology	2	2	78
4	Health Sciences	1	1	12
5	Hepatology	1	1	12

Vineeth Sukrithan

Publications

246

Citations

H-Index

Page 1

	Year	Citations
Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation Tushar D. Bhagat, Si Chen, Matthias Bartenstein, Cancer Research	2017	69
Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia Lohith Bachegowda, Kerry Morrone, Shannon L. Winski, Cancer Research Novel Dual InhibitorMixed-phenotype Acute LeukemiaImmunologyPharmacotherapyMyeloid Neoplasia	2016	45
Targeted Inhibition of the E3 Ligase SCFSkp2/Cks1 Has Antitumor Activity in <i>RB1</i> -Deficient Human and Mouse Small-Cell Lung Cancer Hongling Zhao, Niloy J. Iqbal, Vineeth Sukrithan, Cancer Research	2020	37
An Evaluation of Clinical Efficacy of Immune Checkpoint Inhibitors for Patients with Anaplastic Thyroid Carcinoma Alycia Hatashima, Brianna Archambeau, Heather Armbruster, Thyroid	2022	35
Immune Checkpoint Blockade Is Associated With Durable Responses in Pulmonary Sarcomatoid Carcinoma Vineeth Sukrithan, Jason E. Sandler, Rasim Gucalp, Clinical Lung Cancer Tumor ImmunologyCancer ImmunosurveillanceMedicineImmunologyBronchial Neoplasm	2018	33
A first-in-human phase 1 study of the next-generation RET inhibitor, LOXO-260, in RET inhibitor refractory patients with RET-altered cancers (trial in progress). Nathan A. Pennell, Lori J. Wirth, Justin F. Gainor, Journal of Clinical Oncology PathologyFirst-in-human Phase 1Cancer BiologyTumor BiologyNext-generation Ret Inhibitor	2022	15
Clinical Outcomes of DEB-TACE in Hepatic Metastatic Neuroendocrine Tumors: A 5-Year Single-Institutional Experience Mina S. Makary, Luis E. Regalado, Jonathan Alexánder, Academic Radiology 5-Year Single-institutional ExperienceSurgical OncologyHepatologyMedicineHepatobiliary Tumor	2023	12

Page 1